BAYTRIL(R) IER 2.5-PERCENT - A NEW FORMUL ATION FOR THE ORAL APPLICATION ON SWINE - ANTIBACTERIAL ACTIVITY, PHARMACOKINETIC AND BIOAVAILABILITY

A total of 621 bacterial strains (E. coli, Past. multocida, A. pleurop neumoniae, Bord. bronchiseptica Salmonella spp., Strept. suis, Staph, hyicus, Staph. aureus, M. hyopneumoniae, M. hyosynoviae, M. hyorhinis, Psdm. aeruginosa, Klebs, pneumoniae and Proteus spp.) isolated in 199 4/1995 from swine was checked for Minimal Inhibitory Concentration (MI G) of enrofloxacin and other antiinfectives. From all drugs tested, en rofloxacin exhibited the highest antibacterial activity. Baytril(R) I. E.R. 2.5% (premix) is being marketed in Germany for the following indi cations: pneumonia, respiratory diseases, diarrhoea, septicaemia and e dema disease. MIC(90) for etiologically responsible bacterial species are: M. hyopneumoniae: 0.25 mu g/ml; Past. multocida: 0.015 mu g/ml; A . pleuropneumoniae. 0.03 mu g/ml; E. coli: 0.125 mu g/ml and Salmonell a spp.: 0.06 mu g/ml. Susceptibility data (MIC(50)/MIC(90)) were put i nto relation to enrofloxacin serum and organ levels determined by phar macokinetic studies after food intake of Baytril(R) I.E.R. 2.5% (premi x) in concentrations of 50 and 150 ppm. Two to four hours after intake of medicated food, serum and organ/tissue levels of enrofloxacin were clearly above the MIC(90) of the bacterial species mentioned. Since t he current registration of Baytril(R) I.E.R. 2.5% (premix) a highly po tent antiinfective for oral, individual, or stock treatment in swine i s available.